Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 13/20 | 0.69 |
| ▸ | NTRK2 | Q16620 | 8/20 | 0.64 |
| ▸ | NTRK3 | Q16288 | 3/20 | 0.53 |
| ▸ | RAF1 | P04049 | 2/20 | 0.49 |
| ▸ | AURKA | O14965 | 1/20 | 0.49 |
| ▸ | SRC | P12931 | 1/20 | 0.49 |
| ▸ | BRAF | P15056 | 1/20 | 0.42 |
| ▸ | CSF1R | P07333 | 2/20 | 0.38 |
| ▸ | TEK | Q02763 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL398470 | 0.82 | NTRK1 (1.00) | NTRK1NTRK2NTRK3RAF1AURKA | |
| SCHEMBL398471 | 0.82 | NTRK1 (1.00) | NTRK1NTRK2NTRK3RAF1AURKA | |
| SCHEMBL395051 | 0.81 | NTRK1 (0.45) | NTRK1NTRK2NTRK3RAF1AURKA | |
| SCHEMBL396375 | 0.81 | NTRK1 (0.54) | NTRK1NTRK2NTRK3RAF1AURKA | |
| SCHEMBL397947 | 0.80 | NTRK1 (0.58) | NTRK1NTRK2NTRK3RAF1AURKA | |
| SCHEMBL397888 | 0.78 | NTRK1 (1.00) | NTRK1NTRK2NTRK3RAF1AURKA | |
| SCHEMBL397889 | 0.78 | NTRK1 (1.00) | NTRK1NTRK2NTRK3RAF1AURKA | |
| SCHEMBL395043 | 0.78 | NTRK2 (0.89) | NTRK1NTRK2NTRK3RAF1AURKA | |
| SCHEMBL395044 | 0.78 | NTRK2 (0.89) | NTRK1NTRK2NTRK3RAF1AURKA | |
| SCHEMBL396895 | 0.78 | NTRK1 (0.66) | NTRK1NTRK2NTRK3RAF1AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101608-B2 | 3-(4-Methyl-imidazol-1-yl)-N-{3-[2-oxo-3-(1H-pyrrol-2-ylmethylene)-2,3-dihydro-1H-indol-6-ylamino]-phenyl}-5-trifluoromethyl-benzamide; including benign and malignant proliferative disorders as well as diseases resulting from inappropriate activation of the immune and nervous systems | IRM LLC, a Delware Limited Corporation (BM) | 2012-01-24 | — | — | US | claimed |
| US-8101608-B2 | 3-(4-Methyl-imidazol-1-yl)-N-{3-[2-oxo-3-(1H-pyrrol-2-ylmethylene)-2,3-dihydro-1H-indol-6-ylamino]-phenyl}-5-trifluoromethyl-benzamide; including benign and malignant proliferative disorders as well as diseases resulting from inappropriate activation of the immune and nervous systems | IRM LLC, a Delware Limited Corporation (BM) | 2012-01-24 | — | — | US | disclosed |